Pfenex To Present At The Morgan Stanley Healthcare Conference

SAN DIEGO, Sept. 11, 2015 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that Bertrand C. Liang, chief executive officer of Pfenex will be presenting at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt New York, 109 East 42^nd Street, New York on September 18 at 2:10 pm ET. To access the live webcast link, please log on to www.pfenex.com.

Pfenex has used, and intends to continue to use, its Investor Relations website (http://pfenex.investorroom.com), as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit (http://pfenex.investorroom.com).

About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfnex Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.  

Logo - http://photos.prnewswire.com/prnh/20140715/127348 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pfenex-to-present-at-the-morgan-stanley-healthcare-conference-300141280.html

SOURCE Pfenex Inc.